| 1 |
35444236 | Mitochondrial oxidative phosphorylation is dispensable for survival of CD34+ chronic myeloid leukemia stem and progenitor cells. | 2022 Apr 20 |
1 |
| 2 |
33561320 | PKC-β/Alox5 axis activation promotes Bcr-Abl-independent TKI-resistance in chronic myeloid leukemia. | 2021 Sep |
1 |
| 3 |
33707419 | Exovesicular-Shh confers Imatinib resistance by upregulating Bcl2 expression in chronic myeloid leukemia with variant chromosomes. | 2021 Mar 11 |
2 |
| 4 |
34276365 | Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts. | 2021 |
1 |
| 5 |
34376580 | KITlow Cells Mediate Imatinib Resistance in Gastrointestinal Stromal Tumor. | 2021 Oct |
1 |
| 6 |
34564697 | Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells. | 2021 Sep 25 |
1 |
| 7 |
34771705 | Statins Enhance the Molecular Response in Chronic Myeloid Leukemia when Combined with Tyrosine Kinase Inhibitors. | 2021 Nov 4 |
4 |
| 8 |
31371410 | Leprosy drug clofazimine activates peroxisome proliferator-activated receptor-γ and synergizes with imatinib to inhibit chronic myeloid leukemia cells. | 2020 Apr |
1 |
| 9 |
29423045 | Ovatodiolide targets chronic myeloid leukemia stem cells by epigenetically upregulating hsa-miR-155, suppressing the BCR-ABL fusion gene and dysregulating the PI3K/AKT/mTOR pathway. | 2018 Jan 9 |
1 |
| 10 |
29549929 | Local Anesthetic Drug Inhibits Growth and Survival in Chronic Myeloid Leukemia Through Suppressing PI3K/Akt/mTOR. | 2018 Mar |
1 |
| 11 |
29707154 | Similar expression profiles in CD34+ cells from chronic phase chronic myeloid leukemia patients with and without deep molecular responses to nilotinib. | 2018 Apr 3 |
1 |
| 12 |
30091999 | Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML). | 2018 |
1 |
| 13 |
30574454 | The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia. | 2018 |
2 |
| 14 |
27447561 | Targeting of heme oxygenase-1 attenuates the negative impact of Ikaros isoform 6 in adult BCR-ABL1-positive B-ALL. | 2016 Aug 16 |
2 |
| 15 |
25804236 | Functional activity of CD34-positive cells in chronic myeloid leukemia patients with different response to imatinib therapy. | 2015 Mar |
3 |
| 16 |
26248946 | Silencing of miR-21 sensitizes CML CD34+ stem/progenitor cells to imatinib-induced apoptosis by blocking PI3K/AKT pathway. | 2015 Oct |
3 |
| 17 |
24021153 | Fenretinide targets chronic myeloid leukemia stem/progenitor cells by regulation of redox signaling. | 2014 Apr 20 |
1 |
| 18 |
24527087 | In vitro effects of imatinib on CD34+ cells of patients with chronic myeloid leukemia in the megakaryocytic crisis phase. | 2014 Mar |
2 |
| 19 |
24577437 | CD117 (c-kit) expression on CD34+ cells participates in the cytogenetic response to imatinib in patients with chronic myeloid leukemia in the first chronic phase. | 2014 |
3 |
| 20 |
24667683 | Statins inhibit ABCB1 and ABCG2 drug transporter activity in chronic myeloid leukemia cells and potentiate antileukemic effects of imatinib. | 2014 Jun |
2 |
| 21 |
24675360 | BCR-ABL-induced deregulation of the IL-33/ST2 pathway in CD34+ progenitors from chronic myeloid leukemia patients. | 2014 May 15 |
2 |
| 22 |
25621158 | Imatinib in pulmonary arterial hypertension: c-Kit inhibition. | 2014 Sep |
2 |
| 23 |
23400594 | Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells. | 2013 Apr 1 |
1 |
| 24 |
23409026 | Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era. | 2013 |
3 |
| 25 |
23833101 | CD34-negative solitary fibrous tumour resistant to imatinib. | 2013 Jul 5 |
2 |
| 26 |
21804606 | GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells. | 2012 Mar 15 |
1 |
| 27 |
22033489 | Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors. | 2012 Apr |
1 |
| 28 |
22089930 | Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity. | 2012 Feb |
1 |
| 29 |
22262776 | Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells. | 2012 Mar 8 |
1 |
| 30 |
22372463 | BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia. | 2012 May |
2 |
| 31 |
22425893 | Retention of CD34+ CML stem/progenitor cells during imatinib treatment and rapid decline after treatment with second-generation BCR-ABL inhibitors. | 2012 Sep |
1 |
| 32 |
22467682 | Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness. | 2012 Aug |
1 |
| 33 |
22517301 | Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. | 2012 Nov 1 |
1 |
| 34 |
22708678 | Sulforaphane potentiates the efficacy of imatinib against chronic leukemia cancer stem cells through enhanced abrogation of Wnt/β-catenin function. | 2012 Jul 18 |
1 |
| 35 |
22952296 | The lack of CD34 expression in gastrointestinal stromal tumors is related to cystic degeneration following imatinib use. | 2012 Nov |
2 |
| 36 |
23285088 | Imatinib and nilotinib inhibit hematopoietic progenitor cell growth, but do not prevent adhesion, migration and engraftment of human cord blood CD34+ cells. | 2012 |
2 |
| 37 |
20354828 | Combination of simvastatin and imatinib sensitizes the CD34+ cells in K562 to cell death. | 2011 Jun |
2 |
| 38 |
20407854 | Knockdown of SOD1 sensitizes the CD34+ CML cells to imatinib therapy. | 2011 Sep |
3 |
| 39 |
20684991 | Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients. | 2011 Apr |
1 |
| 40 |
20952511 | p57Kip2 is a downstream effector of BCR-ABL kinase inhibitors in chronic myelogenous leukemia cells. | 2011 Jan |
2 |
| 41 |
21158719 | The gamma catenin/CBP complex maintains survivin transcription in β-catenin deficient/depleted cancer cells. | 2011 Feb |
1 |
| 42 |
19837975 | A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. | 2010 Jan 14 |
1 |
| 43 |
19924144 | Cathepsin B release after imatinib-mediated lysosomal membrane permeabilization triggers BCR-ABL cleavage and elimination of chronic myelogenous leukemia cells. | 2010 Jan |
2 |
| 44 |
20147974 | Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity. | 2010 Apr |
1 |
| 45 |
20574046 | Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate. | 2010 Sep 23 |
1 |
| 46 |
20658954 | Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. | 2010 Aug |
3 |
| 47 |
20869412 | Uptake of synthetic Low Density Lipoprotein by leukemic stem cells--a potential stem cell targeted drug delivery strategy. | 2010 Dec 20 |
2 |
| 48 |
19052557 | Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy. | 2009 May |
1 |
| 49 |
19377081 | The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib. | 2009 Jun |
1 |
| 50 |
19394750 | Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib. | 2009 Jun |
1 |